Donepezil: Uses, Dosage & Side Effects
A cholinesterase inhibitor used to treat symptoms of mild to moderate Alzheimer's disease dementia
Donepezil is a prescription medication used to treat the symptoms of mild to moderate Alzheimer's disease in adults. It belongs to the cholinesterase inhibitor class and works by increasing levels of acetylcholine in the brain, a neurotransmitter essential for memory and cognitive function. Donepezil is recommended by major international guidelines including the National Institute for Health and Care Excellence (NICE), the American Academy of Neurology (AAN), and the European Medicines Agency (EMA). It is listed on the WHO Model List of Essential Medicines and requires a prescription in virtually all countries.
Quick Facts: Donepezil
Key Takeaways
- Donepezil is the most widely prescribed cholinesterase inhibitor for mild to moderate Alzheimer's disease, recommended by NICE, AAN, and EMA guidelines as a first-line symptomatic treatment.
- It works by blocking the enzyme acetylcholinesterase, thereby increasing acetylcholine levels in the brain to improve memory, thinking, and the ability to perform daily activities.
- Treatment starts at 5 mg once daily at bedtime; after at least one month the dose may be increased to 10 mg daily based on clinical response and tolerability.
- The most common side effects are gastrointestinal (diarrhea, nausea) and headache; serious but rare effects include cardiac conduction abnormalities, seizures, and gastrointestinal bleeding.
- Donepezil does not cure or halt Alzheimer's disease progression — it provides symptomatic relief, and benefits gradually diminish if treatment is discontinued.
What Is Donepezil and What Is It Used For?
Donepezil hydrochloride is the most widely prescribed medication for the symptomatic treatment of Alzheimer's disease worldwide. First approved by the U.S. Food and Drug Administration (FDA) in 1996 under the brand name Aricept, donepezil has since become available as a generic medication from numerous manufacturers. It belongs to the cholinesterase inhibitor class of drugs, alongside galantamine and rivastigmine, which together represent the primary pharmacological approach to managing Alzheimer's dementia symptoms.
Alzheimer's disease is characterized by a progressive decline in cognitive function, including memory, reasoning, language, and the ability to carry out daily activities. One of the key neurochemical changes observed in Alzheimer's disease is a significant reduction in the neurotransmitter acetylcholine, which plays a central role in memory formation, attention, and learning. This cholinergic deficit is caused by the degeneration of cholinergic neurons in brain regions critical for cognition, particularly the basal forebrain and hippocampus.
Donepezil works by selectively and reversibly inhibiting acetylcholinesterase (AChE), the enzyme primarily responsible for the hydrolytic breakdown of acetylcholine at cholinergic synapses. By blocking this enzyme, donepezil increases the concentration and duration of action of acetylcholine at neuronal synapses, thereby enhancing cholinergic neurotransmission. This mechanism helps to partially compensate for the loss of cholinergic function that underlies many of the cognitive symptoms of Alzheimer's disease. Donepezil has a high selectivity for AChE over butyrylcholinesterase (BuChE), which contributes to its favorable side effect profile compared to less selective agents.
It is important to understand that donepezil is a symptomatic treatment. It does not modify the underlying neurodegenerative process of Alzheimer's disease, meaning it does not prevent the formation of amyloid plaques or neurofibrillary tangles, nor does it halt the progressive loss of neurons. Clinical trials, including the pivotal studies by Rogers et al. (1998) and the AD2000 Collaborative Group study, have demonstrated that donepezil can produce statistically significant and clinically meaningful improvements in cognitive function (as measured by scales such as the ADAS-cog) and global clinical impression in patients with mild to moderate Alzheimer's disease. The beneficial effects are typically observed within the first 3 to 6 months of treatment and may persist for 12 months or longer in some patients, although the underlying disease continues to progress.
Donepezil is indicated for use in adults only and is not recommended for children or adolescents under 18 years of age, as the safety and efficacy of cholinesterase inhibitors in pediatric populations with cognitive disorders have not been established. The medication has a notably long elimination half-life of approximately 70 hours, which allows for convenient once-daily dosing and provides stable plasma concentrations throughout the day. It is available as film-coated tablets in strengths of 5 mg and 10 mg, and in some markets as orodispersible tablets for patients who have difficulty swallowing.
What Should You Know Before Taking Donepezil?
Contraindications
There is one absolute contraindication to donepezil use: known hypersensitivity (allergy) to donepezil hydrochloride, to piperidine derivatives, or to any of the excipients contained in the tablets. Allergic reactions, although rare, can include skin rash, urticaria (hives), and in very rare cases anaphylaxis. If you have previously experienced an allergic reaction to donepezil or any related compound, you must not take this medication.
Unlike some other medications, donepezil does not have an extensive list of absolute contraindications. However, there are numerous conditions and situations where special caution is required and where the prescribing physician must carefully weigh the potential benefits against the risks before initiating treatment.
Warnings and Precautions
Before starting donepezil, you should inform your doctor if you have or have ever had any of the following conditions, as they may affect whether donepezil is appropriate for you or require closer monitoring during treatment:
- Heart conditions: Donepezil can cause bradycardia (slowing of the heart rate) due to its vagotonic (cholinergic) effect on the heart. Patients with sick sinus syndrome, sinoatrial or atrioventricular block, or other supraventricular conduction disturbances are at particular risk. Additionally, donepezil may prolong the QT interval on electrocardiography, which in rare cases can lead to serious arrhythmias including Torsade de pointes. Tell your doctor if you have irregular or very slow heartbeats, heart failure, a history of heart attack, or a family history of prolonged QT interval.
- Stomach or duodenal ulcers: Cholinesterase inhibitors increase gastric acid secretion by enhancing cholinergic activity. Patients with a history of peptic ulcer disease or those concurrently taking nonsteroidal anti-inflammatory drugs (NSAIDs) may be at increased risk for developing ulcers or gastrointestinal bleeding.
- Epilepsy or seizures: Cholinomimetic drugs, including donepezil, may theoretically lower the seizure threshold. While seizures have been reported as a common side effect, this may also reflect the fact that Alzheimer's disease itself is associated with an increased risk of seizures. Your doctor should be aware of any seizure history.
- Asthma or chronic lung disease: Donepezil's cholinomimetic action may cause bronchoconstriction and increased bronchial secretions. Patients with a history of asthma or chronic obstructive pulmonary disease (COPD) should use this medication with caution.
- Liver disease or hepatitis: Donepezil is extensively metabolized in the liver by the cytochrome P450 enzymes CYP2D6 and CYP3A4. Patients with hepatic impairment may have altered drug metabolism and plasma levels. Those with mild to moderate liver impairment can use donepezil with careful dose titration, but patients with severe hepatic impairment should not use the medication.
- Urinary problems or kidney disease: Cholinomimetic effects can affect bladder function. Patients with urinary outflow obstruction or mild renal impairment should be monitored. Although donepezil is primarily metabolized by the liver, renal impairment may affect drug clearance to some degree.
- Low magnesium or potassium levels: Electrolyte imbalances, particularly hypomagnesemia and hypokalemia, increase the risk of cardiac arrhythmias including QT prolongation. These should be corrected before starting donepezil.
Donepezil may cause prolonged QT interval and Torsade de pointes, potentially life-threatening cardiac arrhythmias. Patients with a personal or family history of QT prolongation, those taking other QT-prolonging medications, or those with electrolyte abnormalities require careful cardiac monitoring during treatment. Report any fainting episodes, palpitations, or irregular heartbeat to your doctor immediately.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, you should consult your doctor before taking donepezil. There are no adequate and well-controlled studies of donepezil in pregnant women. Animal reproductive studies have not demonstrated teratogenic effects, but the potential risk to the human fetus is unknown. Donepezil should only be used during pregnancy if the potential benefit to the mother justifies the potential risk to the fetus.
Donepezil is excreted into breast milk in animal studies, and it is not known whether it is excreted into human breast milk. Breastfeeding is not recommended during donepezil treatment. Women who are breastfeeding should discuss the risks and benefits of continuing treatment with their healthcare provider, who may advise discontinuing breastfeeding or discontinuing the medication.
Driving and Operating Machinery
Alzheimer's disease itself progressively impairs the ability to drive and operate machinery. Patients should not engage in these activities unless their physician determines it is safe to do so. In addition, donepezil may cause fatigue, dizziness, and muscle cramps, which can further impair the ability to drive or use machines safely. If you experience any of these symptoms, you should avoid driving or operating machinery until the symptoms resolve.
Donepezil film-coated tablets contain lactose monohydrate as an excipient. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this formulation.
How Does Donepezil Interact with Other Drugs?
Donepezil can interact with a wide range of other medications, either by pharmacokinetic mechanisms (affecting how the body processes the drug) or pharmacodynamic mechanisms (affecting the drug's actions at its target). It is essential to inform your doctor or pharmacist about all medications you are currently taking, have recently taken, or plan to take, including over-the-counter medicines and herbal products.
Donepezil is metabolized primarily by the hepatic cytochrome P450 enzymes CYP2D6 and CYP3A4, and to a minor extent undergoes glucuronidation. Drugs that inhibit these enzymes can increase donepezil plasma concentrations, potentially enhancing both therapeutic effects and side effects. Conversely, drugs that induce these enzymes can accelerate donepezil metabolism and reduce its efficacy.
Major Interactions
| Drug / Class | Interaction Type | Clinical Significance |
|---|---|---|
| Amiodarone, Sotalol | QT prolongation | Combined use may increase risk of serious cardiac arrhythmias including Torsade de pointes. ECG monitoring recommended. |
| Citalopram, Escitalopram | QT prolongation | Additive QT-prolonging effect. Use with caution; ECG monitoring may be necessary. |
| Pimozide, Sertindole, Ziprasidone | QT prolongation | Antipsychotics that prolong QT interval. Combination should be used with extreme caution. |
| Clarithromycin, Erythromycin | CYP3A4 inhibition + QT | Increases donepezil plasma levels and adds QT-prolonging risk. Monitor closely. |
| Ketoconazole | CYP3A4 inhibition | Potent CYP3A4 inhibitor that can significantly increase donepezil concentrations. Dose adjustment may be needed. |
| Fluoxetine | CYP2D6 inhibition | Inhibits donepezil metabolism via CYP2D6. May increase donepezil levels and side effects. |
| Succinylcholine | Pharmacodynamic | Donepezil may prolong the action of succinylcholine-type muscle relaxants during anesthesia. Inform anesthesiologist. |
| Galantamine, Rivastigmine | Pharmacodynamic | Other cholinesterase inhibitors. Combined use increases cholinergic adverse effects without proven additional benefit. |
Other Notable Interactions
| Drug / Class | Interaction Type | Clinical Significance |
|---|---|---|
| Carbamazepine, Phenytoin | CYP3A4 induction | May decrease donepezil levels by accelerating its hepatic metabolism. Efficacy may be reduced. |
| Rifampicin | CYP3A4 induction | Potent enzyme inducer that can significantly reduce donepezil concentrations and effectiveness. |
| Anticholinergics (e.g., tolterodine) | Pharmacodynamic antagonism | Anticholinergic drugs oppose the mechanism of donepezil and can reduce its therapeutic effect. |
| NSAIDs (ibuprofen, diclofenac) | Additive GI risk | Increased risk of gastrointestinal bleeding when combined with donepezil's gastric acid-increasing effect. |
| Beta-blockers (propranolol, atenolol) | Additive bradycardia | Both classes can slow heart rate. Monitor heart rate and blood pressure during coadministration. |
| Quinidine | CYP2D6 inhibition | Inhibits donepezil metabolism. May lead to increased plasma concentrations. |
If you are scheduled for surgery requiring general anesthesia, you must inform both your surgeon and anesthesiologist that you are taking donepezil. Donepezil can affect the amount of anesthetic medication required and may prolong the neuromuscular blocking effect of succinylcholine-type muscle relaxants. Your medical team will adjust your anesthesia plan accordingly.
Food and Alcohol
Food does not affect the absorption or efficacy of donepezil, so the tablets can be taken with or without meals. However, taking donepezil with the evening meal may help reduce gastrointestinal side effects such as nausea in some patients.
Alcohol consumption should be avoided or minimized during donepezil treatment. Alcohol can worsen the cognitive symptoms of Alzheimer's disease and may amplify central nervous system side effects of donepezil such as dizziness and drowsiness. Additionally, chronic alcohol use can cause liver damage, potentially affecting donepezil metabolism.
What Is the Correct Dosage of Donepezil?
Donepezil should always be taken exactly as prescribed by your doctor or as directed by your pharmacist. The tablet should be swallowed whole with a glass of water, taken in the evening before going to bed. If donepezil causes sleep disturbances such as vivid dreams, nightmares, or insomnia, your doctor may recommend switching to morning dosing instead.
Adults
Starting Dose
The recommended initial dose is 5 mg once daily, taken in the evening. This lower starting dose allows the body to adjust to the medication and minimizes the risk of gastrointestinal side effects. The 5 mg dose should be maintained for at least one month before any dose increase is considered.
Maintenance / Maximum Dose
After at least one month on the starting dose, and following clinical assessment by your doctor, the dose may be increased to 10 mg once daily. This is the maximum recommended daily dose. The decision to increase should be based on your clinical response and tolerability. Not all patients will require or benefit from dose escalation, and some patients may achieve optimal results on the 5 mg dose.
Special Populations
| Patient Group | Recommended Dose | Notes |
|---|---|---|
| Adults (standard) | 5 mg → 10 mg once daily | Start with 5 mg; increase after ≥1 month based on response |
| Elderly (>65 years) | 5 mg → 10 mg once daily | No dose adjustment needed. Most Alzheimer's patients are elderly. |
| Mild to moderate hepatic impairment | Titrate slowly per tolerance | Dose escalation according to individual tolerability; monitor liver function |
| Severe hepatic impairment | Not recommended | No data available; use is not recommended |
| Renal impairment | No dose adjustment | Renal clearance of donepezil is minimal; no adjustment needed |
| Children (<18 years) | Not recommended | Safety and efficacy not established in pediatric population |
Missed Dose
If you forget to take your dose, simply take the next dose at the usual time. Do not take a double dose to make up for a missed one. If you forget to take donepezil for more than one week, do not restart the medication on your own — contact your doctor first, as they may need to reassess your treatment or adjust the dose titration schedule.
Overdose
If you take too much donepezil, or if a child accidentally ingests the medication, contact your local emergency services or poison control center immediately. Bring the medication packaging and remaining tablets with you. Symptoms of overdose may include severe nausea and vomiting, excessive salivation (drooling), sweating, slow heart rate (bradycardia), low blood pressure (feeling faint or dizzy when standing), breathing difficulties, loss of consciousness, and seizures or convulsions. Overdose with cholinesterase inhibitors can result in a cholinergic crisis, which is a medical emergency requiring immediate treatment with atropine.
Stopping Treatment
Do not stop taking donepezil unless your doctor advises you to do so. If donepezil is discontinued, the symptomatic benefits of treatment will gradually fade over a period of weeks. There is no evidence of a rebound effect or withdrawal syndrome when stopping donepezil, but the cognitive and functional improvements gained during treatment may be lost. Your doctor will periodically reassess whether continued treatment is appropriate based on your clinical response and overall health status.
Your doctor will determine how long you should continue taking donepezil. Treatment is typically ongoing as long as a therapeutic benefit is observed. Regular follow-up appointments are essential to evaluate your symptoms, monitor for side effects, and determine whether continued therapy remains clinically appropriate. The decision to discontinue treatment should always be made in consultation with your healthcare provider.
What Are the Side Effects of Donepezil?
Like all medicines, donepezil can cause side effects, although not everyone will experience them. Most side effects are mild to moderate in severity and tend to be transient, particularly during the initial weeks of treatment or after a dose increase. Gastrointestinal side effects are most common and can often be managed by taking the medication with food. The side effects are categorized below by frequency, based on data from clinical trials and post-marketing surveillance.
Contact your doctor or emergency services immediately if you experience: signs of liver damage (nausea, vomiting, loss of appetite, malaise, fever, itching, yellowing of the skin or eyes, dark urine); signs of gastrointestinal bleeding (black, tarry stools or visible blood from the rectum); seizures; fever with muscle stiffness, sweating, or reduced consciousness (neuroleptic malignant syndrome); muscle weakness, tenderness or pain with fever and dark urine (rhabdomyolysis); or fainting with rapid irregular heartbeat.
Very Common
Affects more than 1 in 10 people
- Diarrhea
- Nausea
- Headache
Common
Affects up to 1 in 10 people
- Muscle cramps
- Fatigue
- Insomnia (difficulty sleeping)
- Cold symptoms (common cold)
- Loss of appetite
- Hallucinations (seeing or hearing things that are not there)
- Unusual dreams including nightmares
- Agitation
- Aggressive behavior
- Fainting (syncope)
- Dizziness
- Stomach upset
- Skin rash
- Itching (pruritus)
- Urinary incontinence
- Pain
- Accidents (increased tendency to fall and injure oneself)
- Seizures or convulsions
- Vomiting
- Stomach or duodenal ulcer
- Gastrointestinal bleeding
Uncommon
Affects up to 1 in 100 people
- Slow heart rate (bradycardia)
- Excessive saliva production
Rare
Affects up to 1 in 1,000 people
- Liver damage including hepatitis (inflammation of the liver)
- Stiffness, tremors, or uncontrolled movements (extrapyramidal symptoms), especially of the face and tongue, but also of the limbs
Very Rare
Affects up to 1 in 10,000 people
- Neuroleptic malignant syndrome (fever with muscle stiffness, sweating, or reduced consciousness)
- Rhabdomyolysis (muscle breakdown that can lead to kidney damage; symptoms include muscle weakness, pain, and dark urine)
Frequency Not Known
Cannot be estimated from available data
- Prolonged QT interval on ECG
- Torsade de pointes (rapid irregular heartbeat with fainting)
- Increased libido or hypersexuality
- Pisa syndrome (involuntary sustained lateral bending of the trunk and head)
If you notice any side effects not listed above, or if any side effects become severe or persistent, inform your doctor or pharmacist promptly. Reporting suspected side effects after a medicine has been authorized is important, as it allows continuous monitoring of the medicine's benefit-risk balance. You can report side effects to your national regulatory authority (such as the FDA MedWatch program in the United States, the Yellow Card Scheme in the United Kingdom, or the EMA EudraVigilance system in the European Union).
How Should You Store Donepezil?
Keep donepezil out of the sight and reach of children at all times. This is particularly important given that Alzheimer's patients may share a household with children or grandchildren, and accidental ingestion of donepezil by a child could cause serious cholinergic toxicity requiring emergency medical treatment.
Donepezil film-coated tablets do not require any special storage conditions. They should be stored at room temperature in their original packaging, protected from excessive heat or moisture. Do not use the medication after the expiration date (EXP) printed on the blister pack or outer carton. The expiration date refers to the last day of that month.
Do not dispose of unused or expired donepezil tablets in wastewater (down the sink or toilet) or with household waste. Return unused medication to your pharmacy for safe disposal. These measures help protect the environment and prevent accidental ingestion by others.
What Does Donepezil Contain?
The active substance in donepezil tablets is donepezil hydrochloride. Each film-coated tablet contains either 5 mg or 10 mg of donepezil hydrochloride (as monohydrate). The 5 mg strength is equivalent to 4.56 mg of donepezil base, while the 10 mg strength is equivalent to 9.12 mg of donepezil base.
Inactive Ingredients (Excipients)
The other ingredients in the tablet core are:
- Lactose monohydrate — a filler/diluent
- Microcrystalline cellulose — a binder and filler
- Corn starch (maize starch) — a disintegrant
- Hydroxypropyl cellulose — a binder
- Magnesium stearate — a lubricant
The film coating contains:
- Titanium dioxide (E 171) — a white pigment
- Hypromellose 5cp — a film-forming agent
- Macrogol 400 — a plasticizer
- Yellow iron oxide (E 172) — present in 10 mg tablets only, giving them a yellow-brown color
Tablet Appearance
The 5 mg tablets are white to off-white, round, approximately 7 mm in diameter, biconvex, film-coated tablets. The 10 mg tablets are yellow-brown, round, approximately 9 mm in diameter, biconvex, film-coated tablets. Tablets are available in blister packs of 7, 10, 14, 20, 28, 30, 50, 56, 60, 84, 90, 98, and 100 tablets, or in plastic tablet containers of 250 tablets with a tamper-evident screw cap. Not all pack sizes may be marketed in every country.
Frequently Asked Questions About Donepezil
Donepezil is used to treat the symptoms of mild to moderate Alzheimer's disease in adults. It belongs to the cholinesterase inhibitor class and works by increasing levels of acetylcholine in the brain, a chemical messenger involved in memory, thinking, and judgment. By slowing the breakdown of acetylcholine, donepezil can temporarily improve or stabilize cognitive function and the ability to perform daily activities such as dressing, eating, and communicating. It does not cure Alzheimer's disease or prevent its progression.
The most common side effects of donepezil are diarrhea, nausea, and headache, which occur in more than 1 in 10 patients. Other common side effects include muscle cramps, fatigue, insomnia, vivid dreams or nightmares, loss of appetite, dizziness, and stomach upset. These side effects are typically mild and tend to improve as your body adjusts to the medication, especially during the first few weeks of treatment. Taking donepezil with food and starting at the lower dose of 5 mg can help minimize gastrointestinal symptoms.
Donepezil should be taken as one tablet once daily, preferably in the evening before bedtime, swallowed whole with a glass of water. Treatment usually starts with a 5 mg tablet, and after at least one month your doctor may increase the dose to 10 mg if appropriate. If nightmares or sleep disturbances occur, your doctor may recommend switching to morning dosing. Food does not affect how the medication works, so it can be taken with or without meals. A caregiver can help ensure the medication is taken consistently at the same time each day.
Donepezil should not be combined with other cholinesterase inhibitors such as galantamine or rivastigmine, as this increases the risk of cholinergic side effects without proven additional benefit. However, donepezil may be used together with memantine (an NMDA receptor antagonist), which has a different mechanism of action. Several clinical studies, including the DOMINO trial, have suggested that the combination of donepezil and memantine may provide additional benefits for patients with moderate to severe Alzheimer's disease. Always consult your doctor before adding or changing any medications.
No, donepezil does not cure Alzheimer's disease and does not stop its progression. It is a symptomatic treatment that works by boosting acetylcholine levels in the brain to temporarily improve or maintain cognitive function, memory, and daily functioning. The underlying neurodegenerative process continues despite treatment. If donepezil is stopped, the benefits gradually fade over a period of weeks. Your doctor will regularly reassess whether continued treatment is beneficial. Research into disease-modifying therapies for Alzheimer's continues to be an active area of medical investigation.
All information on this page is based on international medical guidelines and peer-reviewed research. Key sources include the European Medicines Agency (EMA) Summary of Product Characteristics for donepezil, the U.S. FDA prescribing information, NICE technology appraisal guidance TA217 for Alzheimer's disease, the Cochrane systematic review on donepezil for dementia due to Alzheimer's disease, the American Academy of Neurology practice parameters, and the WHO Model List of Essential Medicines. All medical claims have evidence level 1A, the highest quality of evidence based on systematic reviews and randomized controlled trials.
References
This article is based on the following peer-reviewed sources and international guidelines. All information has been verified against current evidence-based medical literature with evidence level 1A.
- European Medicines Agency (EMA). Summary of Product Characteristics: Donepezil hydrochloride. EMA/HMPC. Accessed January 2026.
- U.S. Food and Drug Administration (FDA). Aricept (donepezil hydrochloride) prescribing information. FDA Reference ID: NDA 020690.
- National Institute for Health and Care Excellence (NICE). Technology Appraisal Guidance TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. Updated March 2018.
- Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database of Systematic Reviews. 2018;6:CD001190. doi:10.1002/14651858.CD001190.pub3.
- Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998;50(1):136-145.
- Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease (DOMINO trial). N Engl J Med. 2012;366(10):893-903. doi:10.1056/NEJMoa1106106.
- AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet. 2004;363(9427):2105-2115.
- World Health Organization (WHO). Model List of Essential Medicines, 23rd List. Geneva: WHO; 2023.
- American Academy of Neurology (AAN). Practice parameter: Management of dementia (an evidence-based review). Neurology. 2001;56(9):1154-1166.
- Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008;148(5):370-378.
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in neurology, geriatric medicine, and clinical pharmacology. All content follows the GRADE evidence framework and adheres to international medical guidelines from WHO, EMA, FDA, NICE, and the AAN.
Written by medical professionals with clinical experience in neurology and dementia care. All pharmacological information verified against current EMA SmPC documentation, FDA prescribing information, and NICE technology appraisal guidance.
Independently reviewed by the iMedic Medical Review Board. All clinical claims are supported by evidence level 1A (systematic reviews and meta-analyses of randomized controlled trials). No pharmaceutical company funding or sponsorship.